-transparent.png){kind=logo}
C3H/10T1/2 clone 8 (10T1/2) cells possess Phase I and Phase II xenobiotic metabolizing enzymes associated with the metabolism of polycyclic aromatic hydrocarbons to activated or detoxified species. We compared the metabolism of benzo[a]pyrene (BaP) by these cells to an aflatoxin B1 (AFB1)-transformed line (7SA) and a 3-methylcholanthrene (3-MC)-transformed line (MCA) isolated from carcinogen-treated 10T1/2 cells. Relative to 10T1/2 cells, basal levels of cytochrome P450-mediated aryl hydrocarbon hydroxylase (AHH) were significantly depressed in 7SA cells by about 30%. The inducibility of AHH by BaP treatment was depressed by 30-70% in MCA and 7SA cells over a 36-hr time course. 10T1/2 and MCA cells accumulated similar intracellular amounts of 3-OH-BaP by 12 and 24 hr, respectively; in contrast the accumulation of 3-OH-BaP in 7SA cells was 70% lower. During 36 hr of BaP treatment, total BaP-DNA adduct levels formed in 7SA and MCA cells, determined by 32P-postlabeling analysis, were 90 and 83% lower, respectively, than those found in 10T1/2 cells. These differences in response to BaP treatment were not related to cellular differences in the uptake or efflux of BaP. Relative to 10T1/2 or MCA cells, 7SA cells were found to have at least a twofold increase in UDP-glucuronyltransferase activity, which correlated with the lower intracellular accumulation of 3-OH-BaP and enhanced formation of extracellular polar metabolites. MCA cells had an almost twofold increase in glutathione S-transferase activity relative to parental 10T1/2 cells but produced lower levels of extracellular polar metabolites. These results demonstrate an association between chemical transformation of 10T1/2 cells and altered xenobiotic metabolism. This system may provide an in vitro model for examining the molecular events responsible for the biochemically altered phenotype of the malignantly transformed cell.
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
October 1981,
Archives of biochemistry and biophysics,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
September 1975,
International journal of cancer,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
May 1981,
Cancer research,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
May 1985,
Cell differentiation,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
February 1992,
Cancer research,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
October 1992,
Cancer research,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
June 1987,
European journal of cell biology,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
March 1994,
Comparative biochemistry and physiology. Pharmacology, toxicology and endocrinology,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
January 1982,
Cancer letters,
M B Faletto, and
A E Maccubbin, and
N Ersing, and
F Kouli, and
J A Vangalio, and
H L Gurtoo
January 1985,
Carcinogenesis,
